Selinexor (combination therapy)

Phase 3

Karyopharm Therapeutics Inc. (KPTI)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

KPTIPhase 3$204M

Selinexor (combination therapy) Phase 3 Est. Readout

Selinexor (combination therapy)• Relapsed/Refractory Diffuse Large B-cell Lymphoma501

Dec 2026~Confirmed

CT.gov

00%

Development History

Jul '26

KPTIPhase 3$204M

✗Negative

Selinexor (combination therapy) Phase 3 Est. Readout

Selinexor (combination therapy)• Relapsed/Refractory Diffuse Large B-cell Lymphoma501

Jul 2026~Confirmed

CT.gov

Competitive Landscape

1 competitor in Relapsed/Refractory Diffuse Large B-cell Lymphoma

View Full Landscape

Drug Information

Target Indication

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Clinical Trial

NCT04442022

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

KPTI

Karyopharm Therapeutics Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

SelinexorPhase 3

Multiple Myeloma, Refractory

Selinexor 60 mgPhase 2

Myelofibrosis

KPT-8602Phase 2

Relapsed/Refractory Multiple Myeloma (RRMM)

Selinexor 100 mgPhase 2

Non-Small Cell Lung Carcinoma (NSCLC)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts